However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. 
As a result, Trenbolone Acetate now functions as the primary anabolic compound (aka the ‘workhorse’ compound) that will function to provide the muscle growth throughout the cycle. Trenbolone is strictly an advanced level anabolic steroid, unfit for use by beginners of any type. In this cycle, the Acetate variant of Trenbolone is utilized simply due to its seamless compatibility with Testosterone Propionate. This is because the Propionate and Acetate esters as, previously mentioned early on in this section of the profile, both possess almost identical half-lives (3 days for Trenbolone Acetate and days for Testosterone Propionate). This therefore provides an ease of convenience for the user, as well as smoother injection and administration frequencies. The fact that Testosterone is being utilized at a low enough doses to avoid aromatization, combined with the fact that Trenbolone’s inability to convert into Estrogen at any dose should result in the total elimination of any potential water retention, bloating, gynecomastia or any side effects associated with Estrogen . It is important to note that this cycle in particular is strong enough to be utilized as a bulking cycle, lean mass cycle, or cutting cycle – all without the inflated potential for water retention or other Estrogenic side effects .
Equipoise can produce androgenic side effects such as acne, accelerated hair loss in those predisposed to male pattern baldness and body hair growth. However, the overall androgenicity of this steroid is greatly reduced due to the structural nature that creates EQ in its double bond at the carbon one and two position. Such side effects of Equipoise are still possible, but they will be strongly linked to genetic predisposition, but most will find the threshold is fairly high.
When combating the possible androgenic side effects of Equipoise, it’s important to note they are brought on by the steroid being metabolized by the 5-alpha reductase enzyme. This metabolism will reduce Boldenone to an extremely potent androgen in dihydroboldenone, far more potent than dihydrotestosterone (DHT); however, the total dihydroboldenone activity has proven to be extremely low in human beings. You will further find the androgenic nature of Boldenone will not be significantly affected by 5-alpha reductase inhibitors like Finasteride that are often used to combat the reduction to DHT.
Due to the androgenic nature of Equipoise, women may potentially experience virilization symptoms. Virilization symptoms may include body hair growth, a deepening of the vocal chords and clitoral enlargement. However, the low androgenicity will make this steroid possible to use for some women without such symptoms. At the same time, the extremely slow acting nature of the compound can make it difficult to control regarding blood levels, and alternative steroids may be preferred. Without question, individual sensitivity will dictate a lot. If Equipoise is used and virilization symptoms begin to show, use should be discontinued immediately at their onset and they will fade away. If symptoms begin to show and are ignored, the symptoms may become irreversible.